Injectable Areplivir® was included in the recommendations of the Ministry of Health for the treatment of COVID-19 on December 27, 2021. The first batch of the drug was shipped from the factory on the same day.

Modelax-N® is a new drug in the Promomed Group's gastroenterology portfolio

The effectiveness of Areplivir (favipiravir) in the treatment of COVID-19 was discussed at the 16th National Congress of Therapists

Combalgin® ice is an analgesic gel produced by Promomed Group of Companies

The first domestic injectable drug for the treatment of covid-19 has been registered

Modelform® is the winner of the MARK No. 1 Award IN RUSSIA® – 2021

Areplivir® is the best launch of 2021 in the retail segment according to IQVIA

Promomed Group of Companies has registered the first drug in its portfolio for the treatment of HIV infection

Areplivir, developed by Promomed for the treatment of coronavirus infection, has been registered in Uzbekistan

Promomed Company has registered the first drug in its cancer portfolio for the treatment of widespread cancers

Areplivir, a drug for the treatment of covid-19, has been registered in the Kyrgyz Republic

Promomed Group of Companies has registered the anticoagulant Enoparin

Reduxin Forte is recognized as an innovative product

Areplivir is recognized as an innovative product

Promomed expands its product portfolio

Promomed has developed an injectable form of Areplivir for hospitalized COVID-19 patients

Promomed received the ASNA Award for an innovative drug for the treatment of COVID-19

PROMOMED Group has started developing a new generation antibiotic

Get the most interesting news and publications first!

Sent successfully!

Pharmacovigilance

Press office

To request a press release or interview, please contact our press office